Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Review Series

Targets for cancer therapy

Series edited by William G. Kaelin Jr.

The series reviews a number of cellular processes that provide cancer drug targets, including angiogenesis, cell cycle and checkpoint control, growth factor signaling, and apoptosis. It also discusses target selection based on genomics and the specific case of the Abl inhibitor Gleevec.

Articles in series

Anticancer drug targets: approaching angiogenesis
Eli Keshet, Shmuel A. Ben-Sasson
Eli Keshet, Shmuel A. Ben-Sasson
Published December 1, 1999
Citation Information: J Clin Invest. 1999;104(11):1497-1501. https://doi.org/10.1172/JCI8849.
View: Text | PDF

Anticancer drug targets: approaching angiogenesis

  • Text
  • PDF
Abstract

Authors

Eli Keshet, Shmuel A. Ben-Sasson

×

Choosing anticancer drug targets in the postgenomic era
William G. Kaelin Jr.
William G. Kaelin Jr.
Published December 1, 1999
Citation Information: J Clin Invest. 1999;104(11):1503-1506. https://doi.org/10.1172/JCI8888.
View: Text | PDF

Choosing anticancer drug targets in the postgenomic era

  • Text
  • PDF
Abstract

Authors

William G. Kaelin Jr.

×

Anticancer drug targets: cell cycle and checkpoint control
Geoffrey I. Shapiro, J. Wade Harper
Geoffrey I. Shapiro, J. Wade Harper
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1645-1653. https://doi.org/10.1172/JCI9054.
View: Text | PDF

Anticancer drug targets: cell cycle and checkpoint control

  • Text
  • PDF
Abstract

Authors

Geoffrey I. Shapiro, J. Wade Harper

×

Apoptosis and cancer drug targeting
William R. Sellers, David E. Fisher
William R. Sellers, David E. Fisher
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1655-1661. https://doi.org/10.1172/JCI9053.
View: Text | PDF

Apoptosis and cancer drug targeting

  • Text
  • PDF
Abstract

Authors

William R. Sellers, David E. Fisher

×

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Brian J. Druker, Nicholas B. Lydon
Brian J. Druker, Nicholas B. Lydon
Published January 1, 2000
Citation Information: J Clin Invest. 2000;105(1):3-7. https://doi.org/10.1172/JCI9083.
View: Text | PDF

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

  • Text
  • PDF
Abstract

Authors

Brian J. Druker, Nicholas B. Lydon

×

Anticancer drug targets: growth factors and growth factor signaling
Jackson B. Gibbs
Jackson B. Gibbs
Published January 1, 2000
Citation Information: J Clin Invest. 2000;105(1):9-13. https://doi.org/10.1172/JCI9084.
View: Text | PDF

Anticancer drug targets: growth factors and growth factor signaling

  • Text
  • PDF
Abstract

Authors

Jackson B. Gibbs

×

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts